PATH | VRL
Menu

Development and Clinical Evaluation of Prevnar 13, a 13-Valent Pneumocococcal CRM197 Conjugate Vaccine

This article, published in the Annals of the New York Academy of Sciences, discusses the development, clinical evaluation, and postlicensure impact of the 13-valent pneumococcal CRM(197) protein conjugate vaccine, PCV13, (Prevnar 13®). ABSTRACT ONLY: (Learn how users in developing countries can gain free access to journal articles.)

Author: Gruber WC, Scott DA, Emini EA

Published: 2012

» Visit web page (English)

(Located at www.ncbi.nlm.nih.gov)

Citation: Gruber WC, Scott DA, Emini EA.Development and Clinical Evaluation of Prevnar 13, a 13-Valent Pneumococcal CRM197 Conjuate Vaccine. Annals of the New York Academy of Sciences. 2012;1263:15-26. 

Resource types: Peer-reviewed journal

Diseases/vaccines: Pneumococcus

Topics: Disease/vaccine specific information

Regions: Global